drug · antibody
Cancer Program
Phase 2updated 7mo agoby Mirror Biologics Inc🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 5Antibody drug with a maximum clinical stage of Approval (across all indications), with 9 approved and 146 investigational indications.
targets
Programmed cell death protein 1
all catalysts(0)
nothing on the calendar yet
News(10)
- Merck gets another Phase 3 win for sac-TMT, this time in gastric cancerAn experimental antibody-drug conjugate from Merck has succeeded in another Phase 3 cancer study, potentially helping offset Keytruda's looming patent cliff. Merck said Friday morning that a pivota…endpoints · 17h ago
- Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trialLicensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.biospace · 18h ago
- Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trialLicensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.biospace · 18h ago
- This week in charts: Biotech investors’ China bets are already paying offThis year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.biopharma_dive · 20h ago
- Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsMerck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.biospace · 2d ago
- Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safetySummit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did not include patients that accurately represented the American population.biospace · 2d ago
- Sellas marks 9-month survival benefit in late-stage leukemia vaccine studySellas Life Sciences’ cancer vaccine for acute myeloid leukemia has passed a phase 3 test with a more than nine-month improvement in overall survival.fiercebiotech · 4d ago
- Summit shares fall as FDA rejects closely watched PD-1/VEGF drugThe FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.biopharma_dive · 4d ago
- Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer workEli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.biospace · 4d ago
- Summit's PD-1xVEGF rejected by FDA in lung cancerThe FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.biospace · 5d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that